Jyong Biotech Ltd. Ordinary Shares (MENS) vs Minerva Neurosciences, Inc. (NERV)
Over the past year, NERV outperformed MENS — 57.75% vs -95.66% annualized total return (price plus dividends).
A side-by-side comparison of Jyong Biotech Ltd. Ordinary Shares and Minerva Neurosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
Total return — MENS vs NERV
growth of $100 · dividends reinvested · last 1yMetrics side by side
Did NERV beat MENS?
Over the past year, NERV outperformed MENS — 57.75% vs -95.66% annualized total return (price plus dividends).
Total return (annualized)
| Metric | MENS | NERV |
|---|---|---|
| Total return (1Y) | -95.66% | 57.75% |
| Total return CAGR (3Y) | N/A | -18.88% |
| Total return CAGR (5Y) | N/A | -22.14% |
| Total return CAGR (10Y) | N/A | -29.77% |
MENS is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has NERV beaten MENS?
- Over the past year, NERV outperformed MENS — 57.75% vs -95.66% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.